Diagonal Therapeutics to Present at the Cure HHT’s 15th International Scientific Conference
October 08, 2024 07:00 ET
|
DIAGONAL THERAPEUTICS, INC
Diagonal Therapeutics to Present at the Cure HHT’s 15th International Scientific Conference
Hofseth Biocare ASA: HBC IMMUNOLOGY COMPLETES IN VIVO DRUG LEAD STUDIES FOR PROSTATE CANCER TREATMENT
October 08, 2024 02:45 ET
|
Hofseth Biocare ASA
Ålesund, Norway, 8 October 2024. HBC Immunology (HBCI) is pleased to announce the successful completion of its prostate cancer treatment xenograft studies with its lead peptide FT-002a in a novel...
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
October 07, 2024 16:01 ET
|
Abivax
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation PARIS, France, October 7, 2024, 10:00...
Process Analytical Technology Market Is Expected To Reach a Revenue Of USD 13.8 Bn by 2033, At 14.3% CAGR: Dimension Market Research
October 07, 2024 13:10 ET
|
Dimension Market Research
New York, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Overview: The Process Analytical Technology Market size is expected to reach USD 4.1 billion by 2024 and is further anticipated to reach USD 13.8...
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
October 07, 2024 09:00 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
October 03, 2024 16:01 ET
|
Abivax
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease PARIS, France, October 3, 2024 – 10:00 p.m. CEST – Abivax SA (Euronext Paris:...
Blue Mountain and Apprentice.io Announce Groundbreaking Integration of EAM and MES Technologies, Transforming Asset Performance Management for Life Sciences Manufacturing
October 03, 2024 09:00 ET
|
Blue Mountain; Apprentice.io
Blue Mountain & Apprentice.io announce groundbreaking integration of EAM & MES technologies for life sciences manufacturers.
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank
October 03, 2024 07:00 ET
|
CYTOMED THERAPEUTICS LIMITED
SINGAPORE, Oct. 03, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary...
Kurma Partners achieves first close of new EUR 250 million Biofund IV
October 03, 2024 03:00 ET
|
Kurma Partners
Biofund IV raised EUR 140 million in first closing of EUR 250 million fundBiofund IV to follow Kurma’s proven investment strategy and make 16 to 20 new investmentsFirst three investments of the new...
Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®
October 03, 2024 03:00 ET
|
Enara bio
New investors Pfizer Ventures and M Ventures co-led the financing, with participation from all existing investors including RA Capital, Samsara BioCapital and SV Health InvestorsEnara Bio’s EDAPT®...